Table 1.
Association between TP53 codon 72 status and clinicopathological characteristics
| Total, n (percent) | Arg/Arg, n (percent) | Arg/Pro, n (percent) | Arg/Arg +Arg/Pro, n (percent) | Pro/Pro, n (percent) | Pa | |
| Patients | 557 (100) | 63 (11) | 281 (51) | 344 (62) | 213 (38) | |
| Age (median, year) (n = 557) | 55 | 57 | 56 | 58 | ||
| Tumor size (n = 557) | 0.16 | |||||
| ≤ 2 cm | 202 (36) | 17 (27) | 99 (35) | 116 (33) | 86 (40) | |
| 2 cm to ≤ 5 cm | 286 (51) | 37 (59) | 151 (54) | 188 (55) | 98 (46) | |
| >5 cm | 57 (10) | 6 (9) | 28 (10) | 34 (10) | 23 (11) | |
| Unknown | 12 (2) | 3 (5) | 3 (1) | 6 (2) | 6 (3) | |
| Node status (n = 557) | >0.99 | |||||
| Negative | 321 (58) | 34 (54) | 167 (60) | 201 (58) | 120 (56) | |
| Positive | 198 (35) | 25 (40) | 99 (35) | 124 (36) | 74 (35) | |
| Unknown | 38 (7) | 4 (6) | 15 (5) | 19 (6) | 19 (9) | |
| Histology (n = 557) | 0.98 | |||||
| IDC | 486 (87) | 54 (86) | 246 (87) | 300 (87) | 186 (87) | |
| ILC | 20 (4) | 2 (3) | 10 (4) | 12 (4) | 8 (4) | |
| Others | 51 (9) | 7 (11) | 25 (9) | 32 (9) | 19 (9) | |
| ER status (n = 557) | 0.13 | |||||
| Positive | 344 (62) | 33 (52) | 171 (61) | 204 (59) | 140 (66) | |
| Negative | 181 (32) | 25 (40) | 95 (34) | 120 (35) | 61 (29) | |
| Unknown | 32 (6) | 5 (8) | 15 (5) | 20 (6) | 12 (5) | |
| Grade (n = 289) | 0.27 | |||||
| 1 | 71 (24) | 3 (9) | 48 (32) | 51 (28) | 20 (19) | |
| 2 | 147 (51) | 21 (62) | 67 (45) | 89 (48) | 59 (56) | |
| 3 | 54 (19) | 8 (23) | 28 (19) | 36 (19) | 18 (17) | |
| Unknown | 17 (6) | 2 (6) | 7 (4) | 9 (5) | 8 (8) | |
| p53 IHC (n = 289) | >0.99 | |||||
| Positive | 72 (25) | 15 (44) | 29 (19) | 44 (24) | 28 (27) | |
| Negative | 196 (68) | 19 (56) | 108 (72) | 127 (69) | 69 (66) | |
| Unknown | 21 (7) | 0 (0) | 13 (9) | 13 (7) | 8 (7) |
aArg/Arg and Arg/Pro genotypes compared with Pro/Pro genotype. ER, estrogen receptor; IDC, invasive ductal carcinoma; IHC, immunohistochemistry; ILC, invasive lobular carcinoma.